Participate in Research
Research studies help find new methods for diagnosing, treating, managing, and preventing Crohn's disease and ulcerative colitis. Even the most promising scientific findings must first be proven to be safe and effective before they can be used in the management of inflammatory bowel disease (IBD).
If you are interested in learning more about participating in a research study or clinical trial, speak with your doctor.
For Researchers recruiting patients for study participation
Are you a researcher looking to promote your research study among patients with Crohn's or colitis? Crohn’s and Colitis Canada currently promotes studies conducted by scientists affiliated with academic institutions who have demonstrated proof of ethics approval. Promotion will be via our website. At this time, we cannot promote research study recruitment via email or social media.
To submit a request to have your study promoted by Crohn's and Colitis Canada, complete the online form HERE. Our research programs team will review your request and connect with you about next steps.
Active studies recruiting participants:
- The IMAGINE Network MAGIC Study
What is this Study About?
The IMAGINE Network is currently recruiting healthy individuals along with persons with inMammatory bowel disease (IBD) and irritable bowel syndrome (IBS). Our goal is to recruit 8,000 subjects and will study how three important variables (genes, diet and mental health) impact the gut microbiome and, in turn, how together they impact the disease course.
Who can Participate?
Adults or children with IBD or IBS, or healthy subjects
This study has been approved by the Hamilton Integrated Research Ethics Board (REB #3000).
Primary Contact
Aida Fernandes
fernaa19@mcmaster.ca
Principal Investigator
Paul Moayyedi
McMaster University
- Personalized Anti-Inflammatory Fibres in Ulcerative Colitis
What is this Study About?
The goal of this clinical trial is to determine the clinical effects of two different dietary fibre supplements, acacia gum (AG) and microcrystalline cellulose (MCC), in patients with ulcerative colitis. The main question it aims to answer is: Can the fibre supplements reduce gut inflammation?
Researchers will compare AG and MCC to a placebo (a look-alike substance that contains no fibre) to see if the fibre supplements improve inflammation in ulcerative colitis.
Who can Participate?
- Patients with ulcerative colitis living in Edmonton, AB
- 15-60 years old
- Mild disease or in remission
- Elevated fecal calprotectin (>250 ug/g)
Your Role in this Study
Participants will add their assigned fibre supplement or placebo to their usual diet daily for 6 weeks. They will visit the clinic at baseline, week 3, and week 6 to provide samples (stool, blood) and complete various questionnaires. Participants will receive a gift card if they complete the 6-week trial.
Patients can complete this survey to see if they would be eligible to participate:
https://redcap.link/paif_uc_screening
This study has been approved by the University of Alberta Research Ethics Board (REB #PRO00137948).
Primary Contact
Anissa Armet
aarmet@ualberta.ca
Principal Investigator
Dr. Eytan Wine
University of Alberta / University of Toronto
- Help define the IBD-related burden from a global patient perspective
What is this Study About?
The IBD Disk is a widely used questionnaire that assesses IBD-related burden across 10 categories. However, there are some concerns and limitations about the current version, limiting its usability in clinical practice and research. Therefore, the goal of the IBD Disk 2.0 project is to identify the most important impacts contributing to a high burden of IBD from the perspective of a broad group stakeholders (including people living with IBD, IBD nurses, gastroenterologists specialized in IBD, academic IBD researchers and mental health workers / psychologists in the field of IBD). This is a global initiative aiming to gather the perspective of stakeholders across Europe, America and Australia. To obtain an accurate and comprehensive view of the burden on IBD patients, your input is crucial.
Who can Participate?
Patients with Crohn's disease or Ulcerative Colitis or type unclassified with a minimum age of 18 years can participate in this study.
Your Role in this Study
Participation in this survey study involves completing two rounds by filling out two questionnaires. Completing the survey will take approximately 20 minutes and should be done in one sitting. The first round will close on October 22nd. Participation in this study is anonymous.
You can access the survey for the first round of the IBD Disk 2.0 survey study via this link:
https://www.surveymonkey.com/r/IBD_Disk_2_Round_1
This study has been approved by the UZ/KU Leuven Research Ethics Committee (REB #S70788).
Primary Contact
Manon Vanhaverbeke
manon.vanhaverbeke@kuleuven.be
Principal Investigator
Marc Ferrante
UZ/KU Leuven
- INSPIRE-Flare
What is this Study About?
Get involved in rheumatology research being conducted at the University of Cambridge!
Researchers at the University of Cambridge are conducting groundbreaking research to better understand patient experiences of flares in autoimmune diseases.
Led by Melanie Sloan, Cambridge academic and patient advocate, and supported by a team of leading experts, this study aims to improve understanding of disease flares to improve early recognition and care.
Who can Participate?
Participants must be diagnosed with an autoimmune disease and be over 18 years old.
Your Role in this Study
To take part, you need to complete a survey which asks about how you define flares in your disease, what triggers and prevents flares and the order of symptoms in flares. It should take about 45 minutes to complete, and you can pause or stop at any time.
Everyone who takes part can choose to be entered into a prize draw to win one of four £50 amazon vouchers when the survey closes, which will likely be in early June.
Please click on this link
https://bit.ly/4kOQeyg to take part.
This study was approved by the University of Cambridge Research Ethics Committee (REB # PRE.2025.009).
Primary Contact
Martha Piper
mp2196@cam.ac.uk
Principal Investigator
Melanie Sloan
University of Cambridge